References
- Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
- Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends – an update. Cancer Epidemiol Biomarkers Prev. 2016;25:16–27.
- Navin NE. Cancer genomics: one cell at a time. Genome Biol. 2014;15:452.
- Garraway LA. Genomics-driven oncology: framework for an emerging paradigm. JClin Oncol. 2013;31:1806–1814.
- Gordon BL, Finnerty BM, Aronova A, et al. Genomic medicine for cancer diagnosis. J Surg Oncol. 2015;111:24–30.
- Chio IIC, Tuveson DA. ROS in cancer: the burning question. Trends Mol Med. 2017;23:411–429.
- Gill JG, Piskounova E, Morrison SJ. Cancer, oxidative stress, and metastasis. Cold Spring Harb Symp Quant Biol. 2016;81:163–175.
- Shunmoogam N, Naidoo P, Chilton R. Paraoxonase (PON)-1: a brief overview on genetics, structure, polymorphisms and clinical relevance. Vasc Health Risk Manag. 2018;14:137–143.
- Li HL, Liu DP, Liang CC. Paraoxonase gene polymorphisms, oxidative stress, and diseases. J Mol Med (Berl). 2003;81:766–779.
- Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–269.
- Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–605.
- Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme Paraoxonase-1. Clin Sci. 2004;107:435–447.
- Nishi A, Milner DA, Giovannucci EL, et al. Integration of molecular pathology, epidemiology and social science for global precision medicine. Expert Rev Mol Diagn. 2016;16:11–23.
- Zhang M, Xiong H, Fang L, et al. Paraoxonase 1 (PON1) Q192R gene polymorphism and cancer risk: A meta-analysis based on 30 publications. Asian Pac J Cancer Prev. 2015;16:4457–4463.
- Chen R, Zheng Y, Zhuo L, et al. The association between miR-423 rs6505162 polymorphism and cancer susceptibility: a systematic review and meta-analysis. Oncotarget. 2017;8:40204–40213.
- Wang BS, Liu Z, Xu WX, et al. CYP3A5*3 polymorphism and cancer risk: a meta-analysis and meta-regression. Tumor Biol. 2013;34:2357–2366.
- Jia J, Ren J, Yan D, et al. Association between the XRCC6 polymorphisms and cancer risks: a systematic review and meta-analysis. Med (Baltimore). 2015;94:e283.